ELITE TEST
BANK: Ham’s
Primary Care
Geriatrics (7th
Edition) &
2026/2027
Clinical Standards
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Critical Action" Cheat Sheet
○ 2026/2027 Clinical Paradigm Shifts
● PART II: THE ELITE TEST BANK
○ Block A (Questions 1–28): Foundational Syntax & Application Focus: AGS
Beers Criteria 2026, ADA 2026 Standards, PREVENT-ASCVD, LACE Framework.
○ Block B (Questions 29–58): Professional Simulation Focus: The 5Ms, Atypical
Presentations, Acute Clinical Actions, Prescribing Cascades.
○ Block C (Questions 59–88): Grandmaster Synthesis Focus: Value-Based Care
(UT Austin ACT), OBBBA 2025, High-Acuity Multi-System Failures.
PART I: THE PRIMER
,The "Welcome to the Big Leagues" Hook Amateurs memorize symptoms; elite practitioners
architect clinical, regulatory, and financial survival. This test bank will forge your academic
knowledge into lethal clinical intuition, intercepting high-stakes errors before they reach the
patient. You are about to master the 2026/2027 gerontological landscape, where precision
deprescribing and value-based care separate top-tier clinicians from the rest.
The "Critical Action" Cheat Sheet
● The 2026 Beers Criteria Shift: Stop memorizing "no-go" lists. 2026 mandates actionable
alternatives. Swap Z-drugs for Cognitive Behavioral Therapy for Insomnia (CBT-I); swap
warfarin for DOACs.
● The PREVENT-ASCVD Equation: The legacy Pooled Cohort Equation is obsolete. You
must integrate eGFR and the Social Deprivation Index (SDI) to accurately forecast risk.
● The ADA Adipocentric Paradigm: Shift from strict glucocentric A1C targets to visceral
fat reduction using incretin therapies (GLP-1s). Do not rely on A1C for complex/frail older
adults; prioritize hypoglycemia avoidance and use Continuous Glucose Monitoring
(CGM).
● The OBBBA 2025 Reality: The "One Big Beautiful Bill Act" freezes long-term care
staffing mandates until 2034. Clinical efficiency and value-based care are your only
defenses against systemic collapse.
Framework Legacy Practice 2026/2027 Elite Standard
AGS Beers Criteria Focus on "Avoid" lists Focus on prescribing specific,
non-pharmacologic
alternatives.
Cardiovascular Risk Pooled Cohort Equations PREVENT-ASCVD
(incorporates SDI & eGFR,
removes race).
Diabetes (Older Adults) Universal A1C targets Adipocentric paradigm, CGM
utilization, extreme
hypoglycemia avoidance.
Value-Based Care (ACT) Fee-for-service volume Outcomes that matter most to
patients divided by total costs.
PART II: THE ELITE TEST BANK
Block A: Foundational Syntax & Application
Q1: An 84-year-old male with a history of falls requests a medication to help him sleep. He
previously used zolpidem. According to the 2026 AGS Beers Criteria Alternatives List, which is
the MOST APPROPRIATE INITIAL intervention? A) Prescribe a lower dose of zolpidem (2.5
mg) to minimize fracture risk. B) Initiate Cognitive Behavioral Therapy for Insomnia (CBT-I). C)
Recommend over-the-counter diphenhydramine to avoid prescription sedatives. D) Prescribe an
atypical antipsychotic like quetiapine for off-label sedation.
● The Answer: B (Initiate Cognitive Behavioral Therapy for Insomnia (CBT-I).)
● Distractor Analysis:
○ A is incorrect: Lowering the dose does not eliminate the severe risk of delirium and
fractures associated with Z-drugs in the elderly.
○ C is incorrect: Diphenhydramine is highly anticholinergic, triggering confusion,
urinary retention, and constipation.
○ D is incorrect: Antipsychotics carry a black-box warning for increased stroke risk
, and should never be used for simple insomnia.
The Mentor's Analysis: Sleep architecture degrades with age. Masking this physiological
reality with sedatives guarantees a fall. The 2026 Beers update shifted from merely banning
drugs to demanding safer alternatives. **Professional Intuition: Always fix the behavior before
altering the neurochemistry.
Q2: A 76-year-old female presents for a routine wellness exam. She has no history of
cardiovascular disease. The practitioner calculates her 10-year ASCVD risk. Under 2026
guidelines, which novel variables MUST be included in this calculation using the
PREVENT-ASCVD equations? A) Race and chronological age. B) eGFR and the Social
Deprivation Index (SDI). C) High-sensitivity C-reactive protein (hsCRP) and homocysteine. D)
Left ventricular ejection fraction (LVEF) and BMI.
● The Answer: B (eGFR and the Social Deprivation Index (SDI).)
● Distractor Analysis:
○ A is incorrect: The 2026 PREVENT equations specifically removed race as a
biological variable to address health equity.
○ C is incorrect: While hsCRP is a risk amplifier, it is not a core mandatory variable
required for the baseline equation.
○ D is incorrect: LVEF is used for heart failure management, not primary ASCVD risk
prediction.
The Mentor's Analysis: Cardiovascular risk does not exist in a biological vacuum. The
inclusion of the Social Deprivation Index (SDI) in 2026 formally operationalizes social
determinants of health into objective clinical risk forecasting. Professional Intuition: Your zip
code is often a more aggressive cardiovascular risk factor than your genetic code.
Q3: A 79-year-old female is evaluated for progressive memory loss. Her daughter reports she
frequently gets lost. According to 2026 diagnostic standards, what is the MOST APPROPRIATE
diagnostic step to confirm pathology prior to considering disease-modifying therapies? A) Order
a non-contrast MRI to rule out vascular dementia. B) Administer the Mini-Mental State Exam
(MMSE) to establish a clinical baseline. C) Order a blood-based biomarker panel (e.g., plasma
p-tau217) or an amyloid PET scan. D) Initiate a therapeutic trial of donepezil and monitor for
cognitive improvement.
● The Answer: C (Order a blood-based biomarker panel (e.g., plasma p-tau217) or an
amyloid PET scan.)
● Distractor Analysis:
○ A is incorrect: MRI rules out alternative etiologies (tumors, strokes) but cannot
confirm the presence of amyloid plaques.
○ B is incorrect: The MMSE screens for severity but cannot determine the biological
etiology of the dementia.
○ D is incorrect: A therapeutic trial does not confirm Alzheimer's pathology and delays
definitive diagnosis.
The Mentor's Analysis: The era of purely clinical Alzheimer's diagnosis is over. With the
advent of targeted immunotherapies, confirming the exact biological presence of amyloid is an
absolute prerequisite. Professional Intuition: You cannot treat a molecular target you haven't
measured.
Q4: An 85-year-old resident in a long-term care facility with severe frailty and moderate
cognitive impairment has Type 2 diabetes. According to the 2026 ADA Standards of Care, what
is the MOST APPROPRIATE glycemic management strategy? A) Maintain a strict A1C target of
< 7.0% to prevent microvascular complications. B) Avoid reliance on A1C; base decisions on
avoiding hypoglycemia and symptomatic hyperglycemia. C) Initiate prandial rapid-acting insulin
, to tightly control post-meal glucose spikes. D) Discontinue all antidiabetic agents to prioritize
patient comfort.
● The Answer: B (Avoid reliance on A1C; base decisions on avoiding hypoglycemia and
symptomatic hyperglycemia.)
● Distractor Analysis:
○ A is incorrect: Strict targets in frail, complex older adults increase mortality risk
through severe hypoglycemia.
○ C is incorrect: Adding prandial insulin increases the complexity of the regimen and
dramatically raises the risk of hypoglycemic events.
○ D is incorrect: While de-intensification is key, complete discontinuation may lead to
symptomatic hyperglycemia (e.g., dehydration), which must be managed.
The Mentor's Analysis: In the very elderly and frail, the timeline to benefit from tight glycemic
control exceeds their life expectancy. The immediate threat is a hypoglycemic fall leading to a
hip fracture. Professional Intuition: In the twilight of life, comfort and safety supersede
biochemical perfection.
Q5: An advanced practice registered nurse (APRN) in Texas is establishing an independent
geriatrics clinic. Under the Texas Board of Nursing 2026/2027 regulations, which action is
STRICTLY PROHIBITED? A) Delegating vital sign collection to unlicensed assistive personnel
(UAP). B) Prescribing Schedule II opioids for chronic pain management without a collaborating
physician. C) Operating and maintaining sole ownership of a pain management clinic. D)
Ordering an amyloid PET scan for a patient with suspected Alzheimer's disease.
● The Answer: C (Operating and maintaining sole ownership of a pain management clinic.)
● Distractor Analysis:
○ A is incorrect: Delegation to UAPs in stable environments is explicitly permitted
under Rule 225.
○ B is incorrect: While restrictive, the core absolute prohibition highlighted in recent
Board rules targets facility ownership.
○ D is incorrect: Ordering advanced diagnostics is within the scope of an APRN
managing geriatric syndromes.
The Mentor's Analysis: Scope of practice is not just about clinical capability; it is about
regulatory boundary management. Board Rule 228.1(5) legally bars APRNs from owning or
operating pain management clinics to prevent "pill mill" proliferation. Professional Intuition:
Elite practice requires knowing where your clinical brilliance ends and your legal liability begins.
Q6: A 71-year-old male with a history of atrial fibrillation is currently taking warfarin. His time in
therapeutic range (TTR) is 55%. Based on the 2026 AGS Beers Criteria Updates, what is the
RECOMMENDED pharmacologic adjustment? A) Increase the frequency of INR monitoring to
weekly. B) Transition the patient to a Direct Oral Anticoagulant (DOAC) such as apixaban. C)
Add daily low-dose aspirin to enhance clot prevention. D) Discontinue all anticoagulation due to
the patient's age and fall risk.
● The Answer: B (Transition the patient to a Direct Oral Anticoagulant (DOAC) such as
apixaban.)
● Distractor Analysis:
○ A is incorrect: Closer monitoring does not address the underlying safety profile
difference between warfarin and DOACs.
○ C is incorrect: Adding aspirin to warfarin without a mechanical valve indication
catastrophically increases major bleeding risk.
○ D is incorrect: Age alone is not an absolute contraindication to anticoagulation in
AFib.
BANK: Ham’s
Primary Care
Geriatrics (7th
Edition) &
2026/2027
Clinical Standards
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Critical Action" Cheat Sheet
○ 2026/2027 Clinical Paradigm Shifts
● PART II: THE ELITE TEST BANK
○ Block A (Questions 1–28): Foundational Syntax & Application Focus: AGS
Beers Criteria 2026, ADA 2026 Standards, PREVENT-ASCVD, LACE Framework.
○ Block B (Questions 29–58): Professional Simulation Focus: The 5Ms, Atypical
Presentations, Acute Clinical Actions, Prescribing Cascades.
○ Block C (Questions 59–88): Grandmaster Synthesis Focus: Value-Based Care
(UT Austin ACT), OBBBA 2025, High-Acuity Multi-System Failures.
PART I: THE PRIMER
,The "Welcome to the Big Leagues" Hook Amateurs memorize symptoms; elite practitioners
architect clinical, regulatory, and financial survival. This test bank will forge your academic
knowledge into lethal clinical intuition, intercepting high-stakes errors before they reach the
patient. You are about to master the 2026/2027 gerontological landscape, where precision
deprescribing and value-based care separate top-tier clinicians from the rest.
The "Critical Action" Cheat Sheet
● The 2026 Beers Criteria Shift: Stop memorizing "no-go" lists. 2026 mandates actionable
alternatives. Swap Z-drugs for Cognitive Behavioral Therapy for Insomnia (CBT-I); swap
warfarin for DOACs.
● The PREVENT-ASCVD Equation: The legacy Pooled Cohort Equation is obsolete. You
must integrate eGFR and the Social Deprivation Index (SDI) to accurately forecast risk.
● The ADA Adipocentric Paradigm: Shift from strict glucocentric A1C targets to visceral
fat reduction using incretin therapies (GLP-1s). Do not rely on A1C for complex/frail older
adults; prioritize hypoglycemia avoidance and use Continuous Glucose Monitoring
(CGM).
● The OBBBA 2025 Reality: The "One Big Beautiful Bill Act" freezes long-term care
staffing mandates until 2034. Clinical efficiency and value-based care are your only
defenses against systemic collapse.
Framework Legacy Practice 2026/2027 Elite Standard
AGS Beers Criteria Focus on "Avoid" lists Focus on prescribing specific,
non-pharmacologic
alternatives.
Cardiovascular Risk Pooled Cohort Equations PREVENT-ASCVD
(incorporates SDI & eGFR,
removes race).
Diabetes (Older Adults) Universal A1C targets Adipocentric paradigm, CGM
utilization, extreme
hypoglycemia avoidance.
Value-Based Care (ACT) Fee-for-service volume Outcomes that matter most to
patients divided by total costs.
PART II: THE ELITE TEST BANK
Block A: Foundational Syntax & Application
Q1: An 84-year-old male with a history of falls requests a medication to help him sleep. He
previously used zolpidem. According to the 2026 AGS Beers Criteria Alternatives List, which is
the MOST APPROPRIATE INITIAL intervention? A) Prescribe a lower dose of zolpidem (2.5
mg) to minimize fracture risk. B) Initiate Cognitive Behavioral Therapy for Insomnia (CBT-I). C)
Recommend over-the-counter diphenhydramine to avoid prescription sedatives. D) Prescribe an
atypical antipsychotic like quetiapine for off-label sedation.
● The Answer: B (Initiate Cognitive Behavioral Therapy for Insomnia (CBT-I).)
● Distractor Analysis:
○ A is incorrect: Lowering the dose does not eliminate the severe risk of delirium and
fractures associated with Z-drugs in the elderly.
○ C is incorrect: Diphenhydramine is highly anticholinergic, triggering confusion,
urinary retention, and constipation.
○ D is incorrect: Antipsychotics carry a black-box warning for increased stroke risk
, and should never be used for simple insomnia.
The Mentor's Analysis: Sleep architecture degrades with age. Masking this physiological
reality with sedatives guarantees a fall. The 2026 Beers update shifted from merely banning
drugs to demanding safer alternatives. **Professional Intuition: Always fix the behavior before
altering the neurochemistry.
Q2: A 76-year-old female presents for a routine wellness exam. She has no history of
cardiovascular disease. The practitioner calculates her 10-year ASCVD risk. Under 2026
guidelines, which novel variables MUST be included in this calculation using the
PREVENT-ASCVD equations? A) Race and chronological age. B) eGFR and the Social
Deprivation Index (SDI). C) High-sensitivity C-reactive protein (hsCRP) and homocysteine. D)
Left ventricular ejection fraction (LVEF) and BMI.
● The Answer: B (eGFR and the Social Deprivation Index (SDI).)
● Distractor Analysis:
○ A is incorrect: The 2026 PREVENT equations specifically removed race as a
biological variable to address health equity.
○ C is incorrect: While hsCRP is a risk amplifier, it is not a core mandatory variable
required for the baseline equation.
○ D is incorrect: LVEF is used for heart failure management, not primary ASCVD risk
prediction.
The Mentor's Analysis: Cardiovascular risk does not exist in a biological vacuum. The
inclusion of the Social Deprivation Index (SDI) in 2026 formally operationalizes social
determinants of health into objective clinical risk forecasting. Professional Intuition: Your zip
code is often a more aggressive cardiovascular risk factor than your genetic code.
Q3: A 79-year-old female is evaluated for progressive memory loss. Her daughter reports she
frequently gets lost. According to 2026 diagnostic standards, what is the MOST APPROPRIATE
diagnostic step to confirm pathology prior to considering disease-modifying therapies? A) Order
a non-contrast MRI to rule out vascular dementia. B) Administer the Mini-Mental State Exam
(MMSE) to establish a clinical baseline. C) Order a blood-based biomarker panel (e.g., plasma
p-tau217) or an amyloid PET scan. D) Initiate a therapeutic trial of donepezil and monitor for
cognitive improvement.
● The Answer: C (Order a blood-based biomarker panel (e.g., plasma p-tau217) or an
amyloid PET scan.)
● Distractor Analysis:
○ A is incorrect: MRI rules out alternative etiologies (tumors, strokes) but cannot
confirm the presence of amyloid plaques.
○ B is incorrect: The MMSE screens for severity but cannot determine the biological
etiology of the dementia.
○ D is incorrect: A therapeutic trial does not confirm Alzheimer's pathology and delays
definitive diagnosis.
The Mentor's Analysis: The era of purely clinical Alzheimer's diagnosis is over. With the
advent of targeted immunotherapies, confirming the exact biological presence of amyloid is an
absolute prerequisite. Professional Intuition: You cannot treat a molecular target you haven't
measured.
Q4: An 85-year-old resident in a long-term care facility with severe frailty and moderate
cognitive impairment has Type 2 diabetes. According to the 2026 ADA Standards of Care, what
is the MOST APPROPRIATE glycemic management strategy? A) Maintain a strict A1C target of
< 7.0% to prevent microvascular complications. B) Avoid reliance on A1C; base decisions on
avoiding hypoglycemia and symptomatic hyperglycemia. C) Initiate prandial rapid-acting insulin
, to tightly control post-meal glucose spikes. D) Discontinue all antidiabetic agents to prioritize
patient comfort.
● The Answer: B (Avoid reliance on A1C; base decisions on avoiding hypoglycemia and
symptomatic hyperglycemia.)
● Distractor Analysis:
○ A is incorrect: Strict targets in frail, complex older adults increase mortality risk
through severe hypoglycemia.
○ C is incorrect: Adding prandial insulin increases the complexity of the regimen and
dramatically raises the risk of hypoglycemic events.
○ D is incorrect: While de-intensification is key, complete discontinuation may lead to
symptomatic hyperglycemia (e.g., dehydration), which must be managed.
The Mentor's Analysis: In the very elderly and frail, the timeline to benefit from tight glycemic
control exceeds their life expectancy. The immediate threat is a hypoglycemic fall leading to a
hip fracture. Professional Intuition: In the twilight of life, comfort and safety supersede
biochemical perfection.
Q5: An advanced practice registered nurse (APRN) in Texas is establishing an independent
geriatrics clinic. Under the Texas Board of Nursing 2026/2027 regulations, which action is
STRICTLY PROHIBITED? A) Delegating vital sign collection to unlicensed assistive personnel
(UAP). B) Prescribing Schedule II opioids for chronic pain management without a collaborating
physician. C) Operating and maintaining sole ownership of a pain management clinic. D)
Ordering an amyloid PET scan for a patient with suspected Alzheimer's disease.
● The Answer: C (Operating and maintaining sole ownership of a pain management clinic.)
● Distractor Analysis:
○ A is incorrect: Delegation to UAPs in stable environments is explicitly permitted
under Rule 225.
○ B is incorrect: While restrictive, the core absolute prohibition highlighted in recent
Board rules targets facility ownership.
○ D is incorrect: Ordering advanced diagnostics is within the scope of an APRN
managing geriatric syndromes.
The Mentor's Analysis: Scope of practice is not just about clinical capability; it is about
regulatory boundary management. Board Rule 228.1(5) legally bars APRNs from owning or
operating pain management clinics to prevent "pill mill" proliferation. Professional Intuition:
Elite practice requires knowing where your clinical brilliance ends and your legal liability begins.
Q6: A 71-year-old male with a history of atrial fibrillation is currently taking warfarin. His time in
therapeutic range (TTR) is 55%. Based on the 2026 AGS Beers Criteria Updates, what is the
RECOMMENDED pharmacologic adjustment? A) Increase the frequency of INR monitoring to
weekly. B) Transition the patient to a Direct Oral Anticoagulant (DOAC) such as apixaban. C)
Add daily low-dose aspirin to enhance clot prevention. D) Discontinue all anticoagulation due to
the patient's age and fall risk.
● The Answer: B (Transition the patient to a Direct Oral Anticoagulant (DOAC) such as
apixaban.)
● Distractor Analysis:
○ A is incorrect: Closer monitoring does not address the underlying safety profile
difference between warfarin and DOACs.
○ C is incorrect: Adding aspirin to warfarin without a mechanical valve indication
catastrophically increases major bleeding risk.
○ D is incorrect: Age alone is not an absolute contraindication to anticoagulation in
AFib.
